Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

4
19
0

Year Published

2019
2019
2022
2022

Publication Types

Select...
9

Relationship

3
6

Authors

Journals

citations
Cited by 29 publications
(23 citation statements)
references
References 40 publications
4
19
0
Order By: Relevance
“…All samples presented a spherical and almost spherical shape and had a smooth and slightly flaky surface (Fig 3). Previous studies that obtained PCL microparticles by the simple emulsion/solvent evaporation technique observed the same morphological data [16,29,30]. Unloaded-microparticles had similar morphology and size to formulations F10 and F20.…”
Section: Resultssupporting
confidence: 66%
“…All samples presented a spherical and almost spherical shape and had a smooth and slightly flaky surface (Fig 3). Previous studies that obtained PCL microparticles by the simple emulsion/solvent evaporation technique observed the same morphological data [16,29,30]. Unloaded-microparticles had similar morphology and size to formulations F10 and F20.…”
Section: Resultssupporting
confidence: 66%
“…In general, these physicochemical data were in accordance to those recommended for polymeric nanocapsules considering the preparation method and the nature of polymers used [27]. The interfacial deposition of the preformed polymer method have usually provided nanocapsules of mean diameters between 200 and 300 nm and PDI between 0.2 and 0.3, mainly when poly(lactic-co-glycolic acid) and PCL are chosen as polymers [28]. However, polymeric nanocapsules of larger diameter can be related to the presence of PEG in their composition.…”
Section: Physicochemical Stabilitysupporting
confidence: 53%
“…Therefore, PCLs are more suitable for long term drug delivery system or medical applications. In addition, PCLs have lower cost than PLAs and PLGAs, which is also an advantage according to some research work [ 19 , 31 , 57 , 58 , 59 ].…”
Section: Current Status Of Nanocapsules: Materials and Formulationmentioning
confidence: 99%
“…For example, to limit several side effects, the common oral dosage of cilostazol is 100-mg, twice per day—which represents a disadvantage in treatment compliance. Long-term release of cilostazol for treatment of peripheral arterial disease has been achieved by loading it into nanocapsules assembled by a poly(ε-caprolactone)-poly (ethylene glycol) shell and oil core [ 58 ]. Prolonged and sustained release of the drug over a period of for 6 days has been achieved without burst effects by both mechanisms of polymeric shell degradation and diffusion.…”
Section: Highlighted Applications Of Nanocapsules As Drug Deliverymentioning
confidence: 99%